OncoSil Medical Limited (ASX:OSL): Pancreatic Cancer Device and Clinical Developments in 2026

Aditi Sarkar

14 October 2026 12:24 AM AEDT

OncoSil Medical Limited (ASX:OSL): Pancreatic Cancer Device and Clinical Developments in 2026

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

OncoSil delivers phosphorus-32 beta radiation directly into pancreatic tumours through an implanted device.
The TRIPP-FFX study reported an 82.2% local disease control rate at 16 weeks in its combination-treatment arm.
A July 2026 per-protocol analysis reported median overall survival of 21.3 months for the device plus FOLFIRINOX group.
Australian therapeutic goods approval and manufacturing milestones featured in the company’s 2026 updates.
Clinical evidence, regulatory permissions and hospital adoption remain distinct considerations.

OncoSil Medical Limited (ASX:OSL) develops a single-use brachytherapy device that places radioactive phosphorus-32 microparticles directly inside pancreatic tumours. The device is intended for use alongside chemotherapy in patients with locally advanced, unresectable pancreatic cancer. During 2026, the company reported clinical findings and regulatory developments relevant to the procedure’s availability and use in different treatment settings.

How Localised Beta Radiation Is Delivered

The OncoSil device is implanted into the tumour under endoscopic ultrasound guidance. Its microparticles emit beta radiation within the treatment area, providing a localised approach rather than radiation directed from outside the body. The company describes the technology as a way to deliver radiation into tumour tissue while limiting exposure to surrounding organs. This is a description of the treatment design, not evidence that risk to adjacent tissue is eliminated.

OncoSil Medical Limited (ASX:OSL) develops the device as an adjunct to chemotherapy, not a replacement for systemic treatment. Patient eligibility, clinical protocols and permitted uses depend on the relevant regulatory jurisdiction. The distinction matters because clinical study combinations do not automatically establish an approved indication.

TRIPP-FFX Data Presented in July 2026

In its 6 July 2026 update, OncoSil Medical Limited (ASX:OSL) reported results from the Phase II TRIPP-FFX study of its device alongside FOLFIRINOX chemotherapy. The company stated that the study met its co-primary endpoints covering safety and tolerability, and local disease control at 16 weeks. In the intention-to-treat device-plus-chemotherapy group, local disease control was 82.2%, with median overall survival of 18.2 months.

The new per-protocol analysis, covering participants treated according to the study protocol, recorded median overall survival of 21.3 months in the OncoSil-plus-FOLFIRINOX group. Its 16-week local disease control rate was 85.0%, compared with 85.4% in the FOLFIRINOX-only group. These measures describe different analyses and must not be presented as proof of a survival benefit. The company reported no new safety signals in the updated assessment.

Regulatory Progress and Clinical Evidence

OncoSil Medical Limited (ASX:OSL) announced Australian Therapeutic Goods Administration approval for the OncoSil device in May 2026. Separately, the company said it was progressing a change notification intended to extend its device label to include FOLFIRINOX, subject to regulatory approval. The existing indication and any proposed extension should therefore be distinguished when interpreting TRIPP-FFX results.

In May 2026, the company also presented interim OSPREY registry findings concerning routine clinical use of OncoSil with gemcitabine-based chemotherapy. The registry is observational, so patient outcomes cannot be interpreted as those of a randomised comparison. Evidence from clinical trials and clinical-practice registries contributes different information about safety, feasibility and treatment outcomes.

Manufacturing and Implementation Considerations

September 2026 announcements from OncoSil Medical Limited (ASX:OSL) addressed an ISO 13485 milestone at its Australian manufacturing facility and the treatment of a 100th patient with its device in Spain. Both relate to operational implementation, although neither alone establishes profitability or the pace of future adoption. Manufacturing controls, specialist clinical training, hospital procedures and regulatory requirements are relevant to the delivery of an implantable radioactive medical device.

Key Insights

OncoSil Medical Limited (ASX:OSL) reported 2026 developments spanning localised pancreatic cancer treatment, updated TRIPP-FFX findings and Australian regulatory progress. The data provide evidence about the device in particular treatment and study settings, while prospective regulatory extensions and wider clinical use require separate assessment. Study endpoints, regulatory indications and operating milestones should be interpreted on their own terms.

FAQs

Q:What does OncoSil Medical develop?

A:An implantable brachytherapy device containing phosphorus-32 microparticles for localised radiation delivery to pancreatic tumours.

Q:What did the TRIPP-FFX study assess?

A:It assessed the OncoSil device with FOLFIRINOX chemotherapy, including safety and local disease control.

Q:What was reported for local disease control?

A:The device-plus-FOLFIRINOX arm recorded 82.2% at 16 weeks in the intention-to-treat analysis.

Q:Does trial evaluation mean every combination is approved?

A:No. The approved indication and the scope of any regulatory extension are separate from clinical trial evaluation.

Q:What other 2026 developments were reported?

A:Updates included Australian regulatory approval, observational registry findings and a manufacturing quality milestone.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.